Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Telomere Shortening as a Prognostic Marker in Early Inflammatory Arthritis: Establishing the Stability of Telomeres in Normal Individuals

NCT01982890 is registered in ClinicalTrials.gov with Université de Sherbrooke as lead sponsor.

NCT NCT01982890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01982890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Telomere Shortening as a Prognostic Marker in Early Inflammatory Arthritis: Establishing the Stability of Telomeres in Normal Individuals
Lead sponsor
Université de Sherbrooke
Phase
Observational
Overall status
Enrolling by invitation
Start date
January 4, 2005
Completion date
December 31, 2026
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

telomere length in healthy controls